Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Gliosarcoma 43Glioblastoma 43Brain Neoplasms 29Glioma 23Sarcoma 20Astrocytoma 13Oligodendroglioma 10Central Nervous System Neoplasms 8Colorectal Neoplasms 7Neoplasm Metastasis 6Recurrence 5Stomach Neoplasms 4Neoplasms 4Hemangiosarcoma 4Carcinoma, Hepatocellular 4Sarcoma, Kaposi 3Ovarian Neoplasms 3Osteosarcoma 3Gastrointestinal Stromal Tumors 3Sarcoma, Ewing 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leiomyosarcoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Diffuse Intrinsic Pontine Glioma 2

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Bevacizumab × Sarcoma × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡